- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Debra Patt Discusses Ongoing Pandemic-Related Delays in Cancer Screenings
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses roadblocks to cancer screenings first thrown up by the COVID-19 pandemic in 2020 and that continue to reverberate today.
Although numbers of cancer screenings are improving, they remain down, and these screenings are delayed because the issue is multifaceted: There is diminished capacity to handle screening requests, staffing issues, and social distancing, so that even people who are ready and want to get screened still are delayed in doing so, noted Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, when addressing roadblocks to cancer screenings first thrown up by the COVID-19 pandemic that continue still.
Transcript
Is there any sign that cancer screenings are returning to prepandemic levels?
Cancer screening has been substantially impacted by the pandemic. We know that, as we published early in 2020, that in 2020, rates were dramatically down across the board for breast, colon, prostate, and lung cancer screenings. We have seen levels improve, but they have not yet returned to normal. In fact, so much so that there are delays in even people that want to get screening getting screened. There’s a multifaceted issue that people are still delaying screenings and there is diminished capacity in each place that does cancer screening, to some degree because of social distancing, to some degree because of staffing. And they just can’t flex to accommodate all the people that have delayed, even if they were all ready to go get screened. No, things have not returned to normal, it still does remain a problem, but it’s much better than we saw in 2020.
Patient Satisfaction Higher With Certain Breast Reconstruction Techniques
August 12th 2025Patient satisfaction was higher amongst patients who underwent a chest wall perforator flap reconstruction surgery as part of their breast cancer treatment when compared with other surgical techniques.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Accessing pediatric dermatology care is challenging due to a shortage of specialists and general dermatologists' reluctance to treat children, but increasing their comfort level with seeing children could help bridge the gap, explained Elizabeth Garcia Creighton, of University of Colorado School of Medicine.
Read More
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
